15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering Procept Biorobotics Corp, 5 rate it Buy or better, 7 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. Targets range widely, $20.00 to $51.00 (about 2.5x), a sign of real disagreement on valuation. The average target of $28.50 sits 34% above the current $21.34. The rating mix has stayed broadly stable, with Buy-side ratings easing from 7 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.25 next quarter toward $-1.15 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Moderate Buy
Strong Buy00%
Buy538%
Hold754%
Sell18%
Strong Sell00%
Based on 13 analysts giving stock ratings to Procept Biorobotics Corp.
As of Sep, 5 of 12 firms rate PRCT a Buy (6 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
PRCT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.25
Range $-0.29 – $-0.23 · 10 analysts · -52% YoY
Next period, 10 analysts expect Procept Biorobotics Corp to earn $-0.25 a share (range $-0.29 – $-0.23), versus $-0.53 a year earlier. Full-year consensus is $-1.68, growing to $-1.15 the year after.
REVENUE · NEXT QUARTER
$117.6M
Range $113.5M – $122.4M · 10 analysts · +54% YoY
Revenue is expected to reach $117.6M (range $113.5M – $122.4M), +54.0% year-over-year. Full-year consensus is $395.4M, rising to $476.9M next year.
Top analysts covering Procept Biorobotics Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PRCT.
#1
Matt O'Brien
Piper Sandler · Rank #424
Buy
$25.00+17.2% to target
Overall win rate
25%
+ Follow
#2
Richard Newitter
Truist Securities
Hold
$25.00+17.2% to target
Coverage
—
+ Follow
#3
NT
Nathan Treybeck
Wells Fargo
Hold
$19.00-10.9% to target
Coverage
—
+ Follow
#4
PW
Patrick Wood
Morgan Stanley
Buy
$51.00+139.0% to target
Coverage
—
+ Follow
#5
Vijay Kumar
Evercore ISI Group
Buy
$23.00+7.8% to target
Coverage
—
+ Follow
PRCT stock forecast FAQ
What is PRCT's average 12-month price target?+
The 10 analysts with a live target average $28.50 for Procept Biorobotics Corp over the next 12 months, ranging from a $51.00 high to a $20.00 low.
Is PRCT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 13 analyst ratings, 5 are Buy or Strong Buy, 7 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for PRCT?+
The Street-high target is $51.00 (Morgan Stanley), and the Street-low is $20.00 (UBS). The average of all 10 active targets is $28.50.
How many Wall Street analysts cover PRCT?+
13 analysts have an active rating on Procept Biorobotics Corp, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering PRCT?+
Among analysts who currently cover PRCT, Matt O'Brien of Piper Sandler has the strongest overall Quantellect track record (Rank #424). Their current call is Buy with a $25.00 target.
What is Procept Biorobotics Corp's projected EPS for next quarter?+
The consensus estimate is $-0.25 per share (range $-0.29 – $-0.23) across 10 analysts. Full-year EPS is projected at $-1.68, rising to $-1.15 the following year.
How much revenue is Procept Biorobotics Corp expected to report next quarter?+
Consensus revenue is $117.6M (range $113.5M – $122.4M). Full-year revenue is projected at $395.4M, growing to $476.9M next year.
Have analysts been upgrading or downgrading PRCT lately?+
As of Sep, 5 of 12 firms rate PRCT a Buy (6 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PRCT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
